Association between PLA2G12A Polymorphisms and Schizophrenia in a Han Chinese Population from Northeast China

Guang Yang1☯, Hongqin Xu1,2☯, Huiping Zhang3,4, Qiong Yu1, Yanhua Wu6, Jieping Shi1, Wenwang Rao1, Yueyue You1, Changgui Kou1*, Yaqin Yu1*

1 Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 1163 Xinmin Street, Changchun, 130021, Jilin province, China, 2 Department of Hepatology, First Hospital of Jilin University, Jilin University, Changchun, Jilin, 130021, China, 3 Department of Psychiatry, Yale University School of Medicine, New Haven, United States of America, 4 VA Medical Center, VA Connecticut Healthcare System, West Haven, United States of America, 5 Division of Clinical Epidemiology, First Hospital of Jilin University, Changchun, Jilin, 130021, China

☯ These authors contributed equally to this work.
* yuyq@jlu.edu.cn (YQY); koucg@jlu.edu.cn (CGK)

Abstract

Objective
The purpose of this study was to explore the association between single nucleotide polymorphisms (SNPs) in the phospholipase A2 (PLA2), group XIIA gene (PLA2G12A) and schizophrenia.

Methods
This study included 1,063 schizophrenia patients and 1,103 healthy controls from a Han Chinese Population in Northeast China. Four tagSNPs (rs11728699 in intron 1, synonymous rs2285714 in exon 3, rs3087494 in the 3' UTR, and rs7694620 in the downstream region) in PLA2G12A were selected, and they were genotyped by the MALDI-TOF-MS technology. The Chi-square ($\chi^2$) test and haplotype analysis were performed to analyze the association of PLA2G12A SNPs and schizophrenia using the software packages SPSS 16.0 and Haploview 4.2.

Results
Among the four tagSNPs, only SNP rs3087494 in the 3' UTR of PLA2G12A showed significant differences in both allele frequencies ($\chi^2 = 20.136, P<0.001$) compared to healthy controls. The minor allele G of SNP rs3087494 is potentially a predictive factor for schizophrenia ($OR = 0.753, 95\% CI: 0.665–0.882$). The frequency distribution of haplotypes consisting of specific alleles of two SNPs (rs7694620-rs3087494 or rs3087494-rs2285714), three SNPs (rs7694620-rs3087494-rs2285714 or rs3087494-rs2285714-rs11728699), or all four SNPs (rs7694620-rs3087494-rs2285714-rs11728699) was significantly different between schizophrenia patients and control subjects ($P<0.001$).
Conclusions
Our study demonstrated that PLA2G12A SNPs or haplotypes might influence the susceptibility to schizophrenia in the Han Chinese population from Northeast China.

Introduction
Schizophrenia is a severe and complex psychiatric disorder that is characterized by positive symptoms (such as hallucinations and delusions) and negative symptoms (such as lack of motivation and interest, social withdrawal, and flattened affect) [1]. Schizophrenia is a common disease, with a lifetime prevalence of approximately 1% [2]. This disease has a marked impact on the quality of life and causes a large social and economic burden. Schizophrenia accounts for approximately 2.8% of the global burden of diseases, according to the statistics published by the World Health Organization (WHO) in 2001. Previous studies have consistently demonstrated that the pathogenesis of schizophrenia is closely related to genetic and environmental factors [3, 4]. The heritability of schizophrenia is estimated to be 64–80%, but the genetic basis of schizophrenia is still far from clear because of the lack of specific biological markers. The effect of genetic factors on schizophrenia risk has been demonstrated by a number of family and twin studies. Genome wide association studies (GWAS) have identified a set of common genetic variants predisposing an individual to schizophrenia [5, 6]. Previous studies have reported abnormal metabolic processes in the membrane phospholipids among patients with schizophrenia [7, 8]. Phospholipase A2 (PLA2) is an important enzyme that catalyzes the hydrolysis of the sn-2 acyl bond of phospholipids to release arachidonic acid and lysophospholipids. Gattaz et al [9] first reported an increased PLA2 activity in the serum, plasma, and platelets of psychiatric patients without drug treatment, and several follow-up studies confirmed this finding [7, 10]. Recent studies by Smesny [11] demonstrated the PLA2 activity was significantly associated with brain structure changes in schizophrenia patients. Eckert et al [12] found that the elevated PLA2 activity in the prefrontal cortex caused increased brain cell membrane fluidity in schizophrenia patients. These results indicated that PLA2 played a key role in the pathogenesis of schizophrenia. Numerous studies have shown that schizophrenia is related to activity changes in cytosolic PLA2 [13–15]. However, inconsistent findings on the association of schizophrenia and PLA2 gene polymorphisms were observed, and there were also studies indicating that schizophrenia is not influenced by the activity of cytosolic PLA2 [16–19].

In our previous studies, we found significant associations between PLA2 family gene polymorphisms and schizophrenia, including different clinical symptoms of schizophrenia. For instance, SNP rs1549637 in PLA2G4C, BanI SNP in the PLA2G4A locus, and SNP rs1648833 in PLA2G4B may contribute to the risk of schizophrenia [18]. To extend our previous findings, we further investigated the genetic association between PLA2G12A polymorphisms and schizophrenia, and significant results were obtained.

Materials and Methods
Study population
We recruited 1,063 patients with schizophrenia from the Sixth Hospital of Changchun and 1,103 healthy controls from the First Hospital of Jilin University through a community-based study of the Han Chinese population in the Jilin Province of Northeast China. The patients
were diagnosed independently by at least two experienced psychiatrists according to the diagnostic criteria of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The healthy control subjects were matched to the case subjects by gender and did not have a positive family history of schizophrenia or other mental disorders. All subjects gave written informed consent before participating in this study, which was approved by the Ethics Committee of the School of Public Health, Jilin University. Blood samples were obtained from participants. Demographic information on gender, age, ethnicity, family history and other measures were collected using a structural questionnaire.

DNA extraction and SNP selection
Subjects donated 5 mL of blood for biochemical analysis. Genomic DNA from peripheral blood lymphocytes was extracted using the DNA Extraction Kit (Kangwei Biotech Company, Beijing, China). We selected four tagSNPs in PLA2G12A (rs11728699 in intron 1, synonymous rs2285714 in exon 3, rs3087494 in the 3’ UTR, and rs7694620 in the downstream region) based on linkage disequilibrium (LD) among SNPs in PLA2G12A analyzed using the Haploview 4.2 software (http://hapmap.ncbi.nlm.nih.gov/). The four SNPs we selected also adhered to the following standards: 1) the minor allele frequency of these SNPs was over 10% in the Chinese population with $r^2 > 0.8$ and $D' = 1$, 2) the SNPs were related to the functional involvement in the pathogenesis of schizophrenia, and 3) the SNPs were reported to have associations with other related disorders in previous studies. SNP genotyping was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).

Statistical analyses
Statistical analyses were conducted using the SPSS (Version 16.0, IBM SPSS, IBM Corp, Armonk, NY, USA). The Chi-square ($\chi^2$) test was used to analyze whether there were significant differences in gender distributions between cases and controls. Student’s t-test was used to analyze whether there were significant differences in age between cases and controls. For each SNP, a Hardy-Weinberg equilibrium (HWE) test was conducted in both case and control groups. The Chi-square ($\chi^2$) test was also used to compare SNP allele frequencies and genotype distributions between cases and controls. $P$ values less than 0.05 were considered to be statistically significant. The Bonferroni correction was used to adjust for multiple comparisons.

Results
Subject characteristics
Our study included 2,166 subjects, comprised of 1,063 schizophrenia patients [589 males and 474 females; mean age (±S.D.), 34±12 years] and 1,103 healthy controls [566 males and 537 females; mean age (±S.D.), 36±10 years]. There was no significant difference in the gender distribution between cases and controls ($\chi^2 = 3.65, P = 0.056$). The genotype distributions of the four tagSNPs in the control group were not deviated from the Hardy-Weinberg equilibrium ($P > 0.05$) (Table 1).

The genotype distribution and allele frequency of PLA2G12A tag SNPs
Genotype distributions and allele frequencies of the four tagSNPs in PLA2G12A are shown in Table 2. SNP rs3087494 in the 3’ UTR of PLA2G12A was significantly associated with schizophrenia. The genotype distribution and allele frequency of this SNP were significantly different between cases and controls (genotype distribution comparison: $\chi^2 = 40.43, df = 2, P < 0.001$; allele frequency comparison: $\chi^2 = 20.14, df = 1, P < 0.001$). Nevertheless, the three other SNPs
(rs7694620, rs11728699 and rs2285714) in PLA2G12A were not significantly associated with schizophrenia by either genotype distribution (using additive or dominant models) or allele frequency comparisons between cases and controls.

The four tagSNPs were not located in one haplotype block by linkage disequilibrium (LD) analysis (Table 3). There exists LD between adjacent sites. The four tagSNPs in PLA2G12A formed several haplotype systems. The frequency distributions of the haplotype systems (rs7694620-rs3087494, rs3087494-rs2285714, rs7694620-rs3087494-rs2285714, rs3087494-rs2285714).

Table 1. The Hardy-Weinberg equilibrium results by goodness-of-fit Chi-square tests.

| tag SNPs    | Cases | Controls |
|-------------|-------|----------|
|             | Ho    | He       | \(\chi^2\) | \(P\)   | Ho    | He       | \(\chi^2\) | \(P\)   |
| rs7694620   | 0.443 | 0.492    | 10.37      | 0.001   | 0.472 | 0.492    | 1.88      | 0.171   |
| rs11728699  | 0.456 | 0.455    | 0.01       | 0.942   | 0.428 | 0.453    | 3.18      | 0.075   |
| rs2285714   | 0.343 | 0.343    | 0.00       | 0.987   | 0.322 | 0.341    | 3.57      | 0.059   |
| rs3087494   | 0.382 | 0.489    | 45.44      | <0.001  | 0.495 | 0.500    | 0.11      | 0.739   |

Ho: observed heterozygosity; He: expected heterozygosity; \(df = 1\)

doi:10.1371/journal.pone.0159584.t001

Table 2. Genotype distribution and allele frequency differences between schizophrenia patients and healthy controls for four PLA2G12A SNPs.

| SNPs          | Genotype/Allele | Cases(%) | Controls(%) | \(\chi^2\) | \(P^a\) | OR  | 95%CI  |
|---------------|-----------------|----------|-------------|------------|-------|-----|--------|
|               |                 |          |             |            |       |     | Lower  | Upper  |
| rs7694620     | Genotype       | TT       | 357(34.16)  | 355(32.54) | 1.82  | 0.403| 1.00  | —      |
|               |                 | TC       | 463(44.31)  | 515(47.20) | 0.894 | 0.737| 1.085 | —      |
|               |                 | CC       | 225(21.53)  | 221(20.26) | 1.012 | 0.799| 1.283 | —      |
|               |                 | TC+CC (vsTT) | 688(65.84)  | 736(67.46) | 0.56  | 0.454| 0.923 | 0.771  |
|               | Allele          | T        | 1177(56.32) | 1225(56.14)| 0.01  | 0.908| 1.00  | —      |
|               |                 | C        | 913(43.68)  | 957(43.86) | 0.993 | 0.880| 1.121 | —      |
| rs11728699    | Genotype       | TT       | 128(12.25)  | 145(13.22) | 1.76  | 0.414| 1.00  | —      |
|               |                 | TG       | 477(45.65)  | 470(42.84) | 1.150 | 0.878| 1.506 | —      |
|               |                 | GG       | 440(42.10)  | 482(43.94) | 1.034 | 0.789| 1.355 | —      |
|               |                 | TG+GG(vsTT) | 917(87.75)  | 952(86.78) | 0.45  | 0.501| 1.091 | 0.846  |
|               | Allele          | T        | 733(35.07)  | 760(34.64) | 0.09  | 0.767| 1.00  | —      |
|               |                 | G        | 1357(64.93) | 1434(65.36)| 0.981 | 0.865| 1.113 | —      |
| rs2285714     | Genotype       | CC       | 644(60.87)  | 684(62.13) | 1.73  | 0.422| 1.00  | —      |
|               |                 | TC       | 363(34.31)  | 354(32.15) | 0.918 | 0.766| 1.101 | —      |
|               |                 | TT       | 51(4.82)    | 63(5.72)   | 1.163 | 0.792| 1.708 | —      |
|               |                 | TC+TT(vsCC) | 414(39.13)  | 417(37.87) | 0.36  | 0.549| 0.948 | 0.797  |
|               | Allele          | C        | 1651(78.02) | 1722(78.20)| 0.02  | 0.888| 1.00  | —      |
|               |                 | T        | 465(17.25)  | 480(21.80)| 0.990 | 0.857| 1.143 | —      |
| rs3087494     | Genotype       | AA       | 224(23.33)  | 264(24.74) | 40.43 | <0.001| 1.00  | —      |
|               |                 | AG       | 367(38.23)  | 528(49.48) | 1.221 | 0.977| 1.525 | —      |
|               |                 | GG       | 369(38.44)  | 275(25.78) | 0.632 | 0.499| 0.801 | —      |
|               |                 | AG+GG(vsAA) | 736(76.67)  | 803(75.26)| 0.55  | 0.459| 0.926 | 0.755  |
|               | Allele          | A        | 815(42.45)  | 1056(49.48)| 20.14 | <0.001| 1.00  | —      |
|               |                 | G        | 1105(57.55) | 1078(50.52)| 0.753 | 0.665| 0.882 | —      |

\(a\) Significant \(P\) values (<0.00125, Bonferroni corrected \(\alpha\)) are in bold.

OR = odds ratio; CI = confidence interval.

doi:10.1371/journal.pone.0159584.t002
rs3087494-rs2285714-rs11728699, and rs7694620-rs3087494-rs2285714-rs11728699) were significantly different between cases and controls (P<0.001) (Table 4).

**Gender-specific associations with the four variants**

To investigate whether gender would play a role in the SNP association, we analyzed the statistics in males and females, respectively (Table 5). Furthermore, we found that the frequency distributions of genotypes and alleles at rs3087494 were significantly different between cases and controls in males (P<0.001), but not in females.

**Analysis of the interaction between gender and polymorphism**

In the analysis of the interaction between polymorphism and gender, we found that only rs3087494 had an interaction with gender (P<0.05) and this interaction was negative (OR_{EG} = 0.426). (Table 6)

**Discussion**

In the present study, we conducted a case-control study to examine the effect of four PLA2G12A SNPs on schizophrenia risk in a Han Chinese population. We found that the 3’ UTR SNP rs3087494 was significantly associated with schizophrenia in our sample. In this association study, we found that the G allele of the rs3087494 SNP was associated with a decreased risk of schizophrenia, and this SNP was also detected to confirm its association with schizophrenia in males. Nevertheless, three other PLA2G12A SNPs (rs2285714, rs11728699, and rs7694620) did not show significant associations with schizophrenia. To the best of our knowledge, this is the first report of a significant association of the PLA2G12A SNP rs3087494 with schizophrenia. This finding supports the hypothesis that the PLA2G12A gene may represent a novel susceptibility gene for schizophrenia.

The PLA2G12A gene located on 4q25 encodes a member of the PLA2 gene family. PLAs are important signaling molecules and are related to various pathologies, such as tissue injury, inflammation and Alzheimer’s disease [20–22]. Furthermore, PLAs have been shown to be closely related to the etiology and pathogenesis of schizophrenia. In line with previous studies,

**Table 3. Linkage disequilibrium (LD) of SNPs in PLA2G12A.**

| Distance       | Cases | Controls |
|----------------|-------|----------|
| (bp)           | D’    | r²       | D’    | r²       |
| rs7694620-rs3087494 | 3,302 | 0.779    | 0.601 | 1.00     | 0.771 |
| rs3087494-rs2285714 | 7,189 | 0.992    | 0.205 | 1.00     | 0.275 |
| rs2285714-rs11728699 | 11,081| 0.988    | 0.507 | 0.989    | 0.518 |

doi:10.1371/journal.pone.0159584.t003

**Table 4. The association between PLA2G12A haplotypes and schizophrenia.**

| Haplotypes | Global $\chi^2$ | P       |
|------------|-----------------|---------|
| rs7694620-rs3087494 | 103.641         | <0.001  |
| rs3087494-rs2285714 | 24.831          | <0.001  |
| rs2285714-rs11728699 | 0.176           | 0.916   |
| rs7694620-rs3087494-rs2285714 | 93.734         | <0.001  |
| rs3087494-rs2285714-rs11728699 | 25.050         | <0.001  |
| rs7694620-rs3087494-rs2285714-rs11728699 | 90.070         | <0.001  |

doi:10.1371/journal.pone.0159584.t004
Table 5. Sex-specific genotype distribution and allele frequency differences between schizophrenia patients and healthy controls for four PLA2G12A SNPs.

| Markers and sex | Genotype (%) | Model | OR(95% CI) | \( P^a \) value | Allele | OR(95% CI) | \( P^a \) value |
|-----------------|--------------|-------|------------|-----------------|--------|------------|----------------|
| **rs7694620**   |              |       |            |                 |        |            |                |
| M Case          | 197          | TT    | 1.088      | 0.811–1.459     | 0.573  | 664        | 488            |
| Control         | 163          | TC    | 0.794      | 0.618–1.020     | 0.071  | 608        | 508            |
| F Case          | 192          | CC    | 0.773      | 0.574–1.041     | 0.090  | 513        | 425            |
| Control         | 160          | TC    | 0.920      | 0.709–1.193     | 0.528  | 617        | 449            |
| **rs11728699**  |              |       |            |                 |        |            |                |
| M Case          | 81           | TT    | 1.130      | 0.894–1.429     | 0.306  | 423        | 739            |
| Control         | 72           | TG    | 1.103      | 0.784–1.551     | 0.575  | 386        | 738            |
| F Case          | 47           | GG    | 1.017      | 0.792–1.307     | 0.894  | 310        | 618            |
| Control         | 73           | GG    | 0.713      | 0.483–1.053     | 0.088  | 374        | 696            |
| **rs2285714**   |              |       |            |                 |        |            |                |
| M Case          | 354          | CC    | 1.010      | 0.621–1.643     | 0.968  | 905        | 267            |
| Control         | 359          | TC    | 0.871      | 0.686–1.106     | 0.257  | 889        | 239            |
| F Case          | 290          | TT    | 1.627      | 0.872–3.035     | 0.123  | 746        | 198            |
| Control         | 325          | TT    | 1.039      | 0.807–1.339     | 0.765  | 833        | 241            |
| **rs3087494**   |              |       |            |                 |        |            |                |
| M Case          | 121          | AA    | 0.442      | 0.339–0.575     | **0.000** | 446    | 640            |
| Control         | 143          | AG    | 0.810      | 0.614–1.070     | 0.137  | 565        | 529            |
| F Case          | 103          | GG    | 0.979      | 0.739–1.298     | 0.881  | 369        | 465            |
| Control         | 121          | GG    | 1.082      | 0.800–1.462     | 0.610  | 491        | 549            |

\( ^a \) Significant \( P \) values are in bold.  
OR = odds ratio; M = males; F = females; CI = confidence interval; Dom = dominant model; Rec = recessive model.

doi:10.1371/journal.pone.0159584.t005

Table 6. Logistics regression of the interaction between SNPs in PLA2G12A and gender.

| SNP            | Factor | \( \chi^2 \) | \( P \) | OR   | 95% CI          |
|----------------|--------|--------------|-------|------|----------------|
|                |        |              |       | Lower| Upper          |
| **rs7694620**  | G      | 2.939        | 0.086 | 1.262| 0.967–1.647    |
|                | E      | 1.255        | 0.263 | 0.865| 0.671–1.155    |
|                | EG     | 1.307        | 0.253 | 0.797| 0.540–1.176    |
|                | Constant| 0.261        | 0.610 | 0.957|                |
| **rs11728699** | G      | 0.052        | 0.819 | 0.959| 0.667–1.377    |
|                | E      | 5.089        | 0.024 | 0.572| 0.352–0.929    |
|                | EG     | 2.348        | 0.125 | 1.535| 0.887–2.655    |
|                | Constant| 0.529        | 0.467 | 1.125|                |
| **rs2285714**  | G      | 0.193        | 0.661 | 0.762| 0.226–2.567    |
|                | E      | 2.510        | 0.113 | 0.536| 0.248–1.159    |
|                | EG     | 0.834        | 0.361 | 1.469| 0.644–3.354    |
|                | Constant| 1.295        | 0.255 | 1.921|                |
| **rs3087494**  | G      | 15.885       | 0.000 | 3.700| 1.944–7.039    |
|                | E      | 0.656        | 0.418 | 0.895| 0.685–1.170    |
|                | EG     | 4.328        | 0.037 | 0.645| 0.426–0.975    |
|                | Constant| 0.930        | 0.335 | 0.817|                |

doi:10.1371/journal.pone.0159584.t006
the activity of PLA2 in serum was increased in drug-free schizophrenia and the enzyme activity was decreased after antipsychotic drug treatment [8].

The positioning of susceptibility genes for schizophrenia is one of the key methods of researching its etiology. The increased activity of PLA2 is the result of abnormal phospholipid metabolism [23]. The studies of candidate genes and genome scanning have acquired many positive results. However, these results are poorly replicated and have caused much dispute. One possible explanation is that PLA2 family gene variants only play a minor role in schizophrenia and only high-efficiency statistical analysis or joint analysis of genetic markers could discover their genuine functions. Another possible explanation is that SNPs associated with schizophrenia act only as markers of a real disease locus that is linked to the identified SNPs.

Due to the diversity in regions of linkage disequilibrium in the population, the reproducibility of relevant schizophrenia candidate genes is deficient in different populations. It has been reported that the activity of secretory PLA2 is increased in the blood and the brain tissue of patients with schizophrenia. PLA2 may be related to the pathogenesis of schizophrenia. The PLA2 gene family may contain susceptibility genes for schizophrenia or could be linked with a susceptibility gene.

Genetic association studies of diseases based on individual SNP data analysis may not able to draw a definite conclusion because the information provided by a single SNP is incomplete. Negative results from a specific SNP cannot rule out the possible association of diseases with other surrounding SNPs. Additionally, a positive association between a SNP and a disease does not necessarily indicate a significant impact of that SNP on disease risk because the identified SNP may be in linkage disequilibrium (LD) with a real disease locus that has not been discovered yet. Therefore, we can carry out a more in-depth investigation by performing haplotype analysis. Haplotypes are comprised of a collection of alleles of two or more tightly linked loci on a chromosome, and haplotype blocks are formed by two or more tightly linked SNPs.

Our study investigated whether the four PLA2G12A SNPs were in LD and what the extent of LD was among them. LD analysis revealed that rs7694620 and rs3087494 were tightly linked and rs3087494 and rs2285714 were tightly linked. The frequency distributions of the rs7694620-rs3087494 and rs3087494-rs2285714 haplotype systems in PLA2G12A were significantly different between cases and controls (P<0.001). This finding suggested a significant association of two adjacent haplotype blocks in PLA2G12A with schizophrenia. In addition, both allelic and genotypic association analyses showed a significant association between SNP rs3087494 and schizophrenia. One interesting finding in our study was the interaction effect of rs3087494 and gender. The SNP rs3087494 had a negative interaction with gender. This interaction may weaken the effect of rs3087494 association with schizophrenia.

Our previous findings on the relationship between PLA2 gene family SNPs and schizophrenia suggest that the BanSNP in PLA2G4A was associated with symptoms of schizophrenia but the PLA2G4A SNP rs7542180 was not associated with schizophrenia [24]. SNP rs1648833 in PLA2G4B was associated with schizophrenia in males but SNP rs3816533 in PLA2G4B was not associated with schizophrenia [25]. SNP rs1549637 in PLA2G4C was also found to be associated with schizophrenia, but the positive results failed to be replicated in other case-control studies [26]. SNPs rs4924618 and rs2459692 in PLA2G4D were not significantly associated with schizophrenia. Negative results were obtained from SNP rs4924595 in PLA2G4E as well. In addition, the results from other studies were also inconsistent. Genetic studies suggested that the PLA2G4A gene, coding for a cytosolic form of PLA2, may be associated with schizophrenia [13, 27], although failure to replicate the PLA2G4A SNP association results has been reported [16, 19, 28]. The results from a case-control study in South Korea were in line with the results of previous studies that showed a positive association of PLA2 alleles with schizophrenia [13].
There are several limitations in the present study that should be considered. First, because this is a cross-sectional study, the interpretation of causal relationships between risk factors and schizophrenia is limited. Second, our data were obtained from a cross-sectional study in the Jilin Province and were not representative of adults throughout China. Furthermore, our study was performed at a single center, which may ignore other SNPs in the candidate genes associated with schizophrenia. At the same time, when we collected samples, we did not record enough quantitative traits. Therefore, we have not observed whether the significant SNPs have eQTL effects or are linked to coding variants. Despite these limitations, our current study provides a sufficient sample size to detect this psychiatric marker. More functional genomics and pathogenesis should be performed in future studies.

Conclusions
The genetic association of these genes with schizophrenia should be confirmed further and could be particularly vital for the understanding of the relationship between schizophrenia and PLA2. There is no doubt that more investigations of genetic associations of genes with schizophrenia would be substantially important for the analysis of the membrane phospholipid hypothesis of schizophrenia.

Acknowledgments
We are grateful to the First Hospital of Jilin University and the Sixth Hospital of Changchun for supporting our project.

Author Contributions
Conceived and designed the experiments: GY HQX. Performed the experiments: GY HQX. Analyzed the data: HPZ QY YHW JPS. Contributed reagents/materials/analysis tools: WWR YYY. Wrote the paper: GY. Provided guidance and additional support on this project: HPZ CGK YQY.

References
1. Monti JM, BaHammam AS, Pandi-Perumal SR, Bromundt V, Spence DW, Cardinali DP, et al. Sleep and circadian rhythm dysregulation in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2013; 43:209–16. Epub 2013/01/16. doi:10.1016/j.pnpbp.2012.12.021 PMID: 23318689.
2. van Os J, Kapur S. Schizophrenia. Lancet. 2009; 374(9690):635–45. Epub 2009/08/25. doi:10.1016/s0140-6736(09)60995-8 PMID: 19700006.
3. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008; 40(7):827–34. Epub 2008/06/28. doi:10.1038/ng.171 PMID: 18583979.
4. Arias B, Rosa A, Fananas L. Human genetic variation and mental disorders. Neurotoxicity research. 2002; 4(5–6):523–30. Epub 2003/05/20. doi:10.1080/1029842021000022106 PMID: 12754164.
5. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009; 460(7256):753–7. Epub 2009/07/03. doi: 10.1038/nature08192 PMID: 19571809; PubMed Central PMCID: PMC2775422.
6. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009; 460(7256):744–7. Epub 2009/07/03. doi: 10.1038/nature08186 PMID: 19571808; PubMed Central PMCID: PMC2775330.
7. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia research. 1995; 16(1):1–6. Epub 1995/07/01. PMID: 7547640.
8. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Archives of general psychiatry. 1997; 54(5):487–94. Epub 1997/05/01. PMID: 9152103.
9.Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biological psychiatry. 1990; 28(6):495–501. Epub 1990/09/15. PMID: 2223919.

10. Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophrenia research. 2003; 61(1):1–6. Epub 2003/03/22. PMID: 12648730.

11. Smesny S, Millet B, Nenadic I, Preul C, Kinder D, Lasch J, et al. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. Neuroimage. 2010; 52(4):1314–27. Epub 2010/05/19. doi: 10.1016/j.neuroimage.2010.05.009 PMID: 20478385.

12. Eckert GP, Schaeffer EL, Schmitt A, Maras A, Gattaz WF. Increased brain membrane fluidity in schizophrenia. Psychopharmacology. 2011; 214(1):461–2. Epub 2011/06/29. doi: 10.1007/s00213-011-2507-z PMID: 21710408.

13. Pae CU, Yu HS, Lee KJ, Kim JJ, Lee CU, Lee SJ, et al. BanI polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2004; 28(4):379–41. Epub 2004/07/28. doi: 10.1016/j.pnpbp.2004.05.009 PMID: 15276701.

14. Rybakowski JK, Borkowska A, Czerski PM, Dmitrzak-Weglarz M, Hauser J. The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology. 2003; 47(3):115–9. Epub 2003/05/22. 70578. PMID: 12759552.

15. Wei J, Lee KH, Hemmings GP. Is the cPLA2 gene associated with schizophrenia? Molecular psychiatry. 1998; 3(6):480–1. Epub 1998/12/19. PMID: 9857971.

16. Chowdari KV, Brandstaetter B, Semwal P, Bhatia T, Deshpande S, Reddy R, et al. Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples. Psychiatric genetics. 2001; 11(4):207–12. Epub 2002/01/25. PMID: 11807411.

17. Friebos RM, Moises HW, Gattaz WF, Yang L, Li T, Liu X, et al. Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2. American journal of medical genetics. 2001; 105(3):246–9. Epub 2001/05/16. PMID: 11353443.

18. Tao R, Yu Y, Zhang X, Guo Y, Shi J, Zhang X, et al. Cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2005;137b(1):56–8. Epub 2005/07/07. doi: 10.1002/ajmg.b.30210 PMID: 15999343.

19. Yu YQ, Tao R, Wei J, Xu Q, Liu SZ, Ju GZ, et al. No association between the PTGS2/PLA2G4A locus and schizophrenia in a Chinese population. Prostaglandins, leukotrienes, and essential fatty acids. 2004; 71(6):405–8. Epub 2004/11/03. doi: 10.1016/j.plefa.2004.09.001 PMID: 15519500.

20. Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. Recent progress in phospholipase A2 research: from cells to animals to humans. Progress in lipid research. 2011; 50(2):152–9. Epub 2010/12/28. doi: 10.1016/j.plipres.2010.12.001 PMID: 21185866.

21. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annual review of biochemistry. 2008; 77:495–520. Epub 2008/04/15. doi: 10.1146/annurev.biochem.76.062405.154007 PMID: 18405237.

22. Talib LL, Hototian SR, Joaquim HP, Forlenza OV, Gattaz WF. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients. European archives of psychiatry and clinical neuroscience. 2015; 265(8):701–8. Epub 2015/07/07. doi: 10.1007/s00406-015-0600-6 PMID: 25920742.

23. Yu Y, Tao R, Shi J, Zhang X, Kou C, Guo Y, et al. A genetic study of two calcium-independent cytosolic PLA2 genes in schizophrenia. Prostaglandins, leukotrienes, and essential fatty acids. 2005;73(5):351–8. Epub 2005/08/24. doi: 10.1016/j.plefa.2005.07.003 PMID: 16115752.

24. Kou C, Tao R, Zhang X, Shi J, Yu Q, Yu Y. Association between PLA2G4A gene polymorphism and schizophrenia. Journal of Jilin University(Medicine Edition). 2006; 32(3):448–50.

25. Yu Q., Shi J., Yu Y., Sang H., Zhu G. Analysis on association between PLA2G4B gene polymorphism and schizophrenia. Journal of Jilin University(Medicine Edition). 2010; 36(5), 938–41.

26. Tao R, Yu Y, Zhang X, Shi J, Wei J. Lack of genetic association of the PLA2G4C locus with schizophrenia in case-control samples. Psychiatric genetics. 2010; 20(1):46. E pub 2009/12/18. doi: 10.1097/YPG.0b013e3283351175 PMID: 20016400.

27. Wei J, Hemmings GP. A study of a genetic association between the PTGS2/PLA2G4A locus and schizophrenia. Prostaglandins, leukotrienes, and essential fatty acids. 2004; 70(4):413–5. Epub 2004/03/26. doi: 10.1016/j.plefa.2003.12.018 PMID: 15041036.
28. Price SA, Fox H, St Clair D, Shaw DJ. Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene. Psychiatric genetics. 1997; 7(3):111–4. Epub 1997/11/05. PMID: 9323323.